UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 690

Sortiert nach

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

Cancer chemotherapy and pharmacology, 2019-09, Vol.84 (3), p.487-499

2019

Link zum Volltext

Verfügbarkeit prüfen

Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations

The American journal of surgical pathology, 2020-05, Vol.44 (5), p.641

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer

Gynecologic oncology, 2020-01, Vol.156 (1), p.194-202

2020

Link zum Volltext

Verfügbarkeit prüfen

HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology

The American journal of surgical pathology, 2022-04, Vol.46 (4), p.435

2022

Link zum Volltext

Verfügbarkeit prüfen

POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium

Gynecologic oncology, 2014-07, Vol.134 (1), p.15-19

2014

Link zum Volltext

Verfügbarkeit prüfen

Tumor Genotype and Immune Microenvironment in Pole-ultramutated and MSI-Hypermutated Endometrial Cancers: New Candidates for Checkpoint Blockade Immunotherapy?

Cancer treatment reviews, 2016-07, Vol.48, p.61-68

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Gynecologic oncology, 2010-01, Vol.116 (1), p.15-20

2010

Link zum Volltext

Verfügbarkeit prüfen

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice

Genes & development, 2006-06, Vol.20 (12), p.1569-1574

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathologic Comparison of Lynch Syndrome–associated and “Lynch-like” Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry

The American journal of surgical pathology, 2016-02, Vol.40 (2), p.155-165

2016

Link zum Volltext

Verfügbarkeit prüfen

Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines

International journal of gynecological cancer, 2017-02, Vol.27 (2), p.196-205

2017

Link zum Volltext

Verfügbarkeit prüfen

Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas

The American journal of surgical pathology, 2019-05, Vol.43 (5), p.591

2019

Link zum Volltext

Verfügbarkeit prüfen

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer

Modern pathology, 2013-11, Vol.26 (11), p.1525-1535

2013

Link zum Volltext

Verfügbarkeit prüfen

Integrated Genomic Profiling of Endometrial Carcinoma Associates Aggressive Tumors with Indicators of PI3 Kinase Activation

Proceedings of the National Academy of Sciences - PNAS, 2009-03, Vol.106 (12), p.4834-4839

2009

Link zum Volltext

Verfügbarkeit prüfen

Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma

Human pathology, 2017-09, Vol.67, p.69-77

2017

Link zum Volltext

Verfügbarkeit prüfen

HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway

Scientific reports, 2020-02, Vol.10 (1), p.3576, Article 3576

2020

Link zum Volltext

Verfügbarkeit prüfen

Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

Autophagy, 2017-03, Vol.13 (3), p.608-624

2017

Link zum Volltext

Verfügbarkeit prüfen

Molecular profiles of benign and (pre)malignant endometrial lesions

Carcinogenesis (New York), 2017-03, Vol.38 (3), p.329-335

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies

Gynecologic oncology, 2015-10, Vol.139 (1), p.118-126

2015

Link zum Volltext

Verfügbarkeit prüfen

Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility

The American journal of surgical pathology, 2014-02, Vol.38 (2), p.189-196

2014

Link zum Volltext

Verfügbarkeit prüfen

ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas

Scientific reports, 2021-06, Vol.11 (1), p.11949-11949, Article 11949

2021

Link zum Volltext

Verfügbarkeit prüfen

Visfatin, a potential biomarker and prognostic factor for endometrial cancer

Gynecologic oncology, 2013-06, Vol.129 (3), p.505-512

2013

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

Gynecologic oncology, 2016-07, Vol.142 (1), p.62-69

2016

Link zum Volltext

Verfügbarkeit prüfen

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy

Gynecologic oncology, 2011-05, Vol.121 (2), p.323-327

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Gynecologic oncology, 2015-02, Vol.136 (2), p.246-253

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 690

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(633)
Mit Volltextzugriff
(576)

Publikationsform

Artikel
(690)

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Female
(680)
Humans
(676)
Science & Technology
(582)
Endometrial Neoplasms - Enzymology
(566)
Life Sciences & Biomedicine
(549)
Endometrial Neoplasms - Pathology
(326)
Oncology
(315)
Middle Aged
(277)
Endometrial Cancer
(264)
Aged
(227)
Endometrial Neoplasms - Genetics
(215)
Tumors
(208)
Adult
(204)
Biological And Medical Sciences
(192)
Medical Sciences
(180)
Obstetrics & Gynecology
(163)
Immunohistochemistry
(159)
Gynecology. Andrology. Obstetrics
(144)
Female Genital Diseases
(139)
Cell Line, Tumor
(137)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes

Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer

HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology

POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium

Tumor Genotype and Immune Microenvironment in Pole-ultramutated and MSI-Hypermutated Endometrial Cancers: New Candidates for Checkpoint Blockade Immunotherapy?

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice

Clinicopathologic Comparison of Lynch Syndrome–associated and “Lynch-like” Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry

Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines

Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer

Integrated Genomic Profiling of Endometrial Carcinoma Associates Aggressive Tumors with Indicators of PI3 Kinase Activation

Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma

HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway

Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

Molecular profiles of benign and (pre)malignant endometrial lesions

Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies

Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility

ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas

Visfatin, a potential biomarker and prognostic factor for endometrial cancer

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Suchergebnisse filtern